TKPHF - Takeda's Entyvio meets primary endpoint in post-market study

2023-03-30 11:28:34 ET

• A phase 4 study of Takeda Pharmaceutical Co.'s ( NYSE: TAK ) Entyvio met its primary endpoint in patients with ulcerative colitis.
• Results showed that at week 14, 31% of patients on Entyvio achieved remission from chronic or recurrent pouchitis compared to 10% on placebo.
• Data also showed that at week 14, the difference in improved clinical response was 30 percentage points compared to placebo. At week 34, the difference was 22.
• Results were published in the New England Journal of Medicine .
• Read why Seeking Alpha contributor Individual Trader rates Takeda ( OTCPK:TKPHF ) a hold.

For further details see: